in combination with KEYTRUDA® (pembrolizumab) and chemotherapy for first-line treatment of metastatic non-squamous non-small ...
Thursday announced positive data from INSIGHT-003 Phase I trial, evaluating the addition of Eftilagimod alpha or ...
Media Release Mature data in patients with a minimum follow-up of 22 months (N=21) shows excellent results, well above historical controls and exceeding expectations: Median Overall Survival is 32.9 ...
Immutep (IMMP) stock climbed 11% Thursday after the company reported positive data from two clinical trials of its drug candidate eftilagimod alpha, or efti. Read more here.
in combination with KEYTRUDA and chemotherapy for first-line treatment of metastatic non-squamous non-small cell lung cancer patients. Key data: These results compare favourably to the 22.0-month ...
Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...
The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...
Immutep's INSIGHT-003 Phase 1 trial reports promising survival data for 1L NSCLC treatment using eftilagimod alpha, Keytruda, ...
During a Case-Based Roundtable® event, Matthew Campbell, MD, MS, moderated a discussion on treatment for a 61-year-old ...
The ASX rises on positive US inflation news, Xero ticks up 5% and Bitcoin hits US$93k before cooling off a tad.
The Australian unemployment rate remained ... trial in non-small cell lung cancer showed that its drug eftilagimod alpha ...